Mineral metabolism and outcomes in chronic kidney disease stage 2–4 patients

BMC Nephrology

Table 3 Hazard ratios of the composite outcome of ESRD or mortality

Parameters	Unadjusted	Model 1^a	Model 2^b
Phosphate^d (mg/dL)
0-3.7	1 (reference)	1 (reference)	1 (reference)
3.7-4.2	1.67 (1.03-2.7)*	1.45 (0.82-2.55)	1.5 (0.82-2.74)
>4.2	3.51 (2.21-5.57)*	2.31 (1.31-4.05)*	2.01 (1.08-3.74)*
PTH^e (pg/mL)
1-42	1 (reference)	1 (reference)	1 (reference)
42-65	2.22 (1.01-4.92)*	2.28 (0.79-6.56)	2.3 (0.8-6.63)
65-105	2.13 (0.98-4.64)	3.38 (1.22-9.39)*	3.54 (1.27-9.87)*
>105	7.16 (3.52-14.5)*	6.81 (2.52-18.4)*	6.04 (2.23-16.4)*
25-OH-D^f (ng/mL)
>30	1 (reference)	1 (reference)	1 (reference)
15-30	1.27 (0.7-2.31)	2.25 (0.88-5.71)	2.13 (0.0.84-5.43)
<15	2.28 (1.19-4.37)*	3.27 (1.19-8.96)*	2.85 (1.03-7.84)*

^aadjusted for age, sex, DM, BMI, serum albumin and eGFR (>=45 or <45 mL/min/1.73 m²), ^bModel 1 further adjusted for other mineral parameters in this table. ^dnormal values 2.5-4.6 mg/dL. ^enormal values 15–65 pg/mL, ^fnormal values >=20 ng/mL.*P<0.05.

ISSN: 1471-2369